title: Multimodality Therapy for NSCLC.
abstract: The standard therapy for patients with unrespectable stage III non-small-cell lung cancer (NSCLC) is the combination of chemotherapy and radiotherapy. Although the concurrent use of both treatment modalities has been shown to be superior to sequential therapy, the role for additional chemotherapy, either as induction or as consolidation, remains unclear. Targeted therapy has met limited success in the treatment of unselected patients with stage III NSCLC. New studies using induction therapy with erlotinib or crizotinib for molecularly selected patients and consolidation therapy with checkpoint inhibitors are currently ongoing, and the results are eagerly awaited.
authors.affiliation: Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, 63110, USA.
authors.forename: Lingling
authors.initials: L
authors.lastname: Du
authors.affiliation: Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, 63110, USA.
authors.forename: Saiama N
authors.initials: SN
authors.lastname: Waqar
authors.affiliation: Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, 63110, USA. dmorgens@dom.wustl.edu.
authors.forename: Daniel
authors.initials: D
authors.lastname: Morgensztern
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy*; D059248:Chemoradiotherapy / Q000379:methods / Q000639:trends; D003131:Combined Modality Therapy / Q000379:methods* / Q000639:trends; D006801:Humans; D007167:Immunotherapy / Q000379:methods / Q000639:trends; D008175:Lung Neoplasms / Q000628:therapy*; D058990:Molecular Targeted Therapy / Q000379:methods / Q000639:trends
keywords: Chemoradiotherapy; Immunotherapy; Molecularly targeted therapy; Stage III NSCLC